Rapid infection diagnosis in preterm babies

Thursday, 19 December, 2019 | Supplied by: Oxford Nanopore Technologies


..jpg

Scientists and clinicians at the Norwich Research Park, UK, have pioneered a new method for profiling the microbiome of preterm babies that can significantly speed up the identification of infections and indicate more effective treatments.

By harnessing next-generation sequencing techniques, the team from the Quadram Institute and the Earlham Institute (EI) showed that they can rapidly and reliably identify the microbes present in a preterm baby’s stool sample that may cause life-threatening conditions such as sepsis or necrotising enterocolitis (NEC). The method also uncovers the presence of antimicrobial resistance genes — vital information needed to select the most effective treatment.

Using Oxford Nanopore Technologies’ MinION portable sequencing device, coupled with bespoke software to analyse the sequence data in real time, data can be obtained in under five hours. With current methods taking up to 48 hours, developing this platform for routine use in a clinical setting would allow faster and tailored antimicrobial treatments to be used.

“Preterm babies are born with underdeveloped gut physiology [and] immunity, and have an altered gut microbiota, all of which increase risk of life-threatening infections. Time is of the essence in detecting or diagnosing infections,” said Dr Lindsay Hall from the Quadram Institute. “Not only could our approach be more effective, it will also reduce the use of antibiotics and help slow the rise of antimicrobial resistance.”

Dr Richard Leggett, Group Leader at EI, added, “With the MinION and our own analysis pipeline (NanoOK RT, developed specifically for this work), we can go from faecal sample to pathogen and antimicrobial resistance (AMR) profile in just four to five hours… We can also take advantage of the MinION’s long DNA reads to place AMR genes within host bacteria, enabling better understanding of antibiotic resistance.”

“Nanopore sequencing is an interesting technology because it provides useful data so quickly,” continued Dr Matthew D Clark, former Head of Technology Development at EI. “We were excited to see how well it could perform on clinical samples with our custom software. It hasn’t escaped our attention that because it is cheap, small and low powered it could be uniquely useful in lower and middle-income countries.”

To test their platform, the researchers used the portable MinION to carry out shotgun metagenomics on mock microbial communities. Shotgun metagenomics analyses the genomic sequence from a mixed collection of organisms — in this case, 20 different microbes. Having confirmed that the MinION approach worked, the researchers progressed to using faecal samples obtained from preterm babies, collected by the Norfolk and Norwich University Hospital’s Neonatal Intensive Care Unit (NICU).

The method, published in the journal Nature Microbiology, discerned between healthy babies and those diagnosed with NEC or sepsis, with the healthy babies having a strong population of beneficial Bifidobacterium and the others harbouring either E. cloacae or Klebsiella pneumoniae, both of which can cause life-threatening infections.

Professor Paul Clarke, Consultant Neonatologist and Research Lead at the Norfolk and Norwich University Hospital NICU and the University of East Anglia, said, “Preterm babies are a group at high risk of dangerous infection. More than 90% of our preterm babies are presently treated with antibiotics, yet in retrospect most did not need them. This study is important because it raises the hope that we might soon have available the technology that could help us to discern at a much earlier stage which babies really need antibiotics, and which do not need them. This could save many babies from getting antibiotics they did not need and would be an important advance in helping limit AMR.”

The system facilitates sampling over a period of time, so that changes in the microbiota profile can be monitored. This is useful for monitoring pathogenic bacteria, but it also lets researchers see how other interventions affect the microbiome over time. For example, it can monitor the effect of antibiotics on the overall microbial profile or measure the effects of probiotic supplementation.

Shotgun metagenomics doesn’t just profile the species diversity. In the study, the researchers were particularly interested in profiling the genes that confer antibiotic resistance in the microbiome — known as the ‘resistome’. Klebsiella, in particular, is of concern as it is becoming increasingly resistant to multiple antimicrobials. An expansion of shotgun metagenomics could therefore help in surveillance for AMR in these clinical settings.

The development of the platform for rapid, portable microbiota profiling brings its use in a clinical setting closer, though more trials at different locations are required before it can be adopted as a routine diagnostic tool. However, there is clear potential for its deployment to save lives in the clinical setting.

Image credit: ©stock.adobe.com/au/Steve Lovegrove

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Online: nanoporetech.com
Phone: +44 845 034 7900
Related Products

Restek Resprep PLR SPE products

Laboratory professionals can simultaneously remove phospholipids and proteins in a single, simple...

Greiner Bio-One NanoShuttle-PL for magnetic 3D cell culture

The core technology of Greiner Bio-One's magnetic 3D cell culture is the magnetisation of...

EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric)

EpiGentek's EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric) is a complete set...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd